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Patent Eligibility: Exploring the Intersection Between 
Patent Law and Biomedical Data 




The world was fundamentally changed by the rampant spread of COVID-19 in 2020. This is not the first 
and will not be the last time the world is faced with a pandemic. Thus, it is essential to take the necessary 
steps now to be prepared in the future. This Note will address how patent law can protect inventions 
incorporating the biomedical data to prevent future pandemics. The Note compares U.S. and European 
Patent Regimes to determine which system is better at protecting biomedical data. Lastly, this Note 
proposes changes to the U.S. Patent Regime to help increase its compatibility with biomedical data. 
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I. INTRODUCTION 
We currently find ourselves in the middle of a global pandemic with no 
knowledge of its ultimate ramifications or scope. A year into this public health crisis, 
COVID-19 continues to reshape our lives.1 The adverse impact on “people’s 
livelihood, their health, and our food systems” has resulted in unprecedented 
economic and social disruption.2 Across the globe, there have been efforts to mitigate 
the detrimental effects of this invisible virus. Notwithstanding these efforts, those 
charged with developing and implementing mitigation strategies continue to come 
up short as COVID-19 has claimed the lives of millions of people.3 Given the 
unknown nature of COVID-19 and the spread of the virus, the world is functioning 
in a state of shock and frenzy, while searching for vaccines that will end the resulting 
devastation.4 
As pathogens continue to move from animals to humans, new infectious viral 
outbreaks will occur.5 Despite additional viral outbreaks looming in the distance, 
including variant COVID-19 strains, the country’s leadership has failed to prepare 
                                                          
* Erin A. Napoleon is a J.D. Candidate for the Class of 2022 at the University of Pittsburgh School 
of Law. 
1 Rolling updates on coronavirus disease (COVID-19), WORLD HEALTH ORG. (July 31, 2020), 
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen (Declaring 
COVID-19 a pandemic on March 11, 2020). 
2 Impact of COVID-19 on people’s livelihoods, their health and our food systems, WORLD HEALTH 
ORG. (Oct. 13, 2020), https://www.who.int/news/item/13-10-2020-impact-of-covid-19-on-people’s-
livelihoods-their-health-and-our-food-systems. 
3 CDC COVID Data Tracker, CTRS. FOR DISEASE CONTROL & PREVENTION, https://covid.cdc.gov/ 
covid-data-tracker/#cases_casesper100klast7days. 
4 Prosper Junior Bakiny, Amid the Coronavirus Frenzy, Novavax Remains a Risky Bet, MOTLEY 
FOOL (Mar. 6, 2020, 10:45 AM), https://www.fool.com/investing/2020/03/06/amid-the-coronavirus-
frenzy-novavax-remains-a-risk.aspx. 
5 Pandemic Prediction and Forecasting Science and Technology Working Group, Towards 
Epidemic Prediction: Federal Efforts and Opportunities in Outbreak Modeling, NAT’L SCI. & TECH. 
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its citizens for the next surge and follow-on pandemics. In this era of great scientific 
and medical advances, the products of such advances should be used to combat not 
only the COVID-19 pandemic, but also future pandemics. The rise and accessibility 
of biomedical data6 can help further this goal through computer-based models and 
inventions protected by patent law. Incentivizing and motivating scientists and 
researchers to continue searching for strains of well-known viruses or new viruses 
through the protections afforded by patent law, will help ensure that the U.S. 
healthcare system is not surprised and ill-prepared when the next pandemic arrives. 
This Note explores the concept of using both patent law and biomedical data 
emanating from new technologies, research and discoveries in efforts to prevent 
future pandemics. As a result, this Note seeks to provide a clearer understanding of 
the intersection between biomedical data and patent law. In addition, this Note seeks 
to address the question of how patent law can afford protections to inventions 
incorporating biomedical data used to prevent global viral and infectious outbreaks. 
In addressing this question, a comparison of the U.S. and European Patent Regimes 
will be provided to determine which system is better suited to protect biomedical 
data. Finally, this Note will analyze ways in which modifications to the American 
patent system can help increase its compatibility with biomedical data. 
II. PANDEMICS AND PATENT LAW 
The world has been plagued by pandemics for millennia. However, modern 
medicine and the implementation of pandemic response plans have mitigated the 
detrimental effects of recent viral outbreaks.7 In addition, the rise of patent law as a 
means for protecting the “architectural components” of vaccine discoveries has 
helped to prevent widespread global outbreaks.8 Such protections create a 
mechanism for motivating researchers to develop cures. This section provides an 
overview of modern pandemics and methods by which the public health community 
has sought to mitigate the detrimental effects of global viral outbreaks. This is done 
                                                          
6 See Lisa Larrimore Ouellette, Access to Bio-Knowledge: From Gene Patents to Biomedical 
Materials, STAN. TECH. L. REV. 3, 18 (2010) (defining biomedical data as “gene sequences, information 
about what a gene encodes, protein structures, research papers, and clinical trial results for 
pharmaceuticals); see also Sharona Hoffman & Andy Podgurski, The Use and Misuse of Biomedical Data, 
39 AM. J.L. & MED. 497, 499 (2013) (defining biomedical data as the compilation of electronic health 
records and genomic data). 
7 CDC Pandemic Tools, CTRS. FOR DISEASE CONTROL & PREVENTION (Apr. 20, 2020), https:// 
www.cdc.gov/flu/pandemic-resources/pandemic-resources.html. 
8 Eileen M. Kane, Preparing or Pandemic Influenza: Achieving Clinical Equity in an Influenza 
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by utilizing, in part, patent law as a means of protecting the research and 
methodologies used in developing vaccines and cures. 
A. Modern Pandemics 
One of the first pandemics occurring in recent time is related to Severe Acute 
Respiratory Syndrome (SARS). SARS is a viral illness that attacks the respiratory 
system.9 Researchers believe that SARS originated in bats, which then transmitted 
the virus to small mammals handled by humans.10 This virus was first detected in 
China in February 2003 and eventually spread to four other countries.11 While the 
spread of this virus was not long lasting, nearly 800 deaths resulted.12 
The H1N1 virus (swine flu) was first detected in the United States in 2009.13 
Even though other strains of influenza had existed both in the United States and 
globally, the strain that caused swine flu was due to a unique combination of genes 
not previously detected in humans or animals.14 The detrimental effects of this 
pandemic were felt not only domestically, but also internationally. The Centers for 
Disease Control (CDC) estimated that worldwide about 151,700,400 people died 
from the swine flu, with the United States making up about 0.008% of the total 
deaths.15 While the World Health Organization (WHO) officially declared the end of 
the H1N1 global pandemic on August 10, 2010, the virus still continues to circulate 
as the seasonal flu, resulting in hospitalizations and deaths yearly.16 The Food and 
Drug Administration (FDA) approved the Rapivab vaccine as a treatment for H1N1 
on December 22, 2014.17 
                                                          
9 SARS Basics Fact Sheet, CTRS. FOR DISEASE CONTROL & PREVENTION (Dec. 6, 2017), https:// 
www.cdc.gov/sars/about/fs-sars.html. 
10 Chien-Te Tseng et al., Immunization with SARS Coronavirus Vaccines Leads to Pulmonary 
Immunopathology on Challenge with the SARS Virus, PLOS ONE (Apr. 20, 2012), https://www.ncbi.nlm 
.nih.gov/pmc/articles/PMC3335060/. 
11 Severe Acute Respiratory Syndrome (SARS), WORLD HEALTH ORG. [WHO], https://www.who 
.int/health-topics/severe-acute-respiratory-syndrome#tab=tab_1. 
12 Tseng et al., supra note 10. 
13 2009 H1N1 Pandemic (H1N1pdm09 virus), CTRS. FOR DISEASE CONTROL & PREVENTION 




17 Charles Patrick Davis & Melissa Conrad Stöppler, Swine Flu (Swine Influenza A [H1N1 and 






J o u r n a l  o f  T e c h n o l o g y  L a w  &  P o l i c y  
Volume XXI – 2020-2021 ● ISSN 2164-800X (online) 










The next notable viral outbreak occurred in 2014. The Ebola Virus Disease 
originated in West Africa and was characterized as the largest epidemic in African 
history.18 Ebola is primarily transmitted through direct contact with blood and bodily 
fluids of infected people.19 While Ebola was not deemed a pandemic due to its heavy 
concentration in Africa, the virus spread to other parts of the world including Italy, 
Spain, the United Kingdom, and the United States.20 Ebola caused more than 11,000 
deaths worldwide.21 
Even though the Ebola outbreak occurred in 2014, the FDA did not approve a 
vaccination to treat this virus until 2019.22 Clinical studies and research led the FDA 
to approve Ervebo for the treatment of Ebola virus.23 Subsequent to FDA approval, 
Merck sought patent protection for the Ervebo vaccine, which was granted on 
September 6, 2011.24 Despite the minimal presence of Ebola virus today, 
“vaccination is essential to help prevent outbreaks and to stop the Ebola virus from 
spreading when outbreaks do occur.”25 The research used to derive the vaccination 
can “help create a model for future studies under similar circumstances.”26 
Most recently, COVID-19 has proven to be one of the most lethal modern 
global pandemics. COVID-19 is an infectious viral disease caused by the respiratory 
pathogen, SARS-CoV-2.27 The SARS-CoV-2 virus typically causes relatively mild 
infection, however the present strain, referred to as coronavirus, is novel and can lead 
                                                          
18 2014–2016 Ebola Outbreak in West Africa, CTRS. FOR DISEASE CONTROL & PREVENTION 
(Mar. 8, 2019), https://www.cdc.gov/vhf/ebola/history/2014-2016-outbreak/index.html. 
19 First FDA-Approved Vaccine for the Prevention of Ebola Virus Disease, Marking a Critical 
Milestone in Public Health Preparedness and Response, U.S. FOOD & DRUG ADMIN. (Dec. 19, 2019), 
https://www.fda.gov/news-events/press-announcements/first-fda-approved-vaccine-prevention-ebola-
virus-disease-marking-critical-milestone-public-health. 
20 CTRS. FOR DISEASE CONTROL & PREVENTION, supra note 18. 
21 U.S. FOOD & DRUG ADMIN., supra note 19. 
22 Id. 
23 Id. 
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to severe respiratory failure and ultimately death.28 As of the time of this writing, 
there have been 3,295,681 deaths globally attributed to the coronavirus, with about 
18% of those deaths occurring in the United States.29 
Knowledge of the patented SARS genomic sequence30 and how the virus 
impacts the human body from the first SARS pandemic in 2003, gave scientists a 
great advantage when they began searching for cures for COVID-19.31 As of the date 
of writing this publication, the FDA has approved the Moderna and Pfizer vaccines 
for emergency use authorization, both of which employ the use of messenger RNA 
(mRNA).32 The FDA has also approved the emergency use of the Johnson and 
Johnson vaccine. The AstraZeneca and Novavax COVID-19 vaccines are currently 
in phase 3 clinical trials.33 While the Pfizer and Moderna vaccines themselves are 
not patented, technologies used in the development of the vaccine are subject to 
patent protection.34 For example, both Pfizer and Moderna hold a patent in lipid 
nanoparticle (NP) technology, which delivers mRNA to cells and instructs the cells 
to produce the SARS-CoV-2 spike protein.35 Additionally, Pfizer holds patents in 
mRNA structure, formulations, and manufacturing.36 Similarly, Moderna possesses 
7 patents for COVID-19 related technologies and processes.37 In combating modern 
pandemics, patent law and the protections it affords to biomedical data has played a 
                                                          
28 Daniel DiMaio, Lynn W. Enquist & Terence S. Dermody, A New Coronavirus Emerges, This 
Time Causing a Pandemic, ANN. REV. VIROLOGY (Sept. 2020), https://www.annualreviews.org/doi/10 
.1146/annurev-vi-07-042020-10000. 
29 Coronavirus Resource Center, JOHNS HOPKINS U. & MED., https://coronavirus.jhu.edu/. 
30 U.S. Patent No. 7,897,744 (filed Apr. 28, 2004) (issued Mar. 1, 2011). 
31 Jocelyn Solis-Moreira, How did we develop a COVID-19 vaccine so quickly?, MEDICAL NEWS 
TODAY (Dec. 15, 2020), https://www.medicalnewstoday.com/articles/how-did-we-develop-a-covid-19-
vaccine-so-quickly#Funding-for-COVID-19-vaccine-research. 
32 Understanding mRNA Covid-19 Vaccines, CTRS. FOR DISEASE CONTROL & PREVENTION 
(Dec. 18, 2020), https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/mrna.html; see 
also Messenger RNA, National Human Genome Research Institute, https://www.genome.gov/ genetics-
glossary/messenger-rna (defining mRNA as “a single-stranded RNA molecule that is complementary to 
one of the DNA strands of a gene”). 
33 Different COVID-19 Vaccines, CTRS. FOR DISEASE CONTROL & PREVENTION (Jan. 15, 2021), 
https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines.html. 
34 See Mario Gaviria & Buruc Kilic, BioNtTch and Pfizer’s BNT162 Vaccine Patent Landscape, 
PUBLIC CITIZEN (Nov. 16, 2020), https://www.citizen.org/article/biontech-and-pfizers-bnt162-vaccine-
patent-landscape/; Mario Gaviria & Buruc Kilic, mRNA-1273 Vaccine Patent Landscape (for NIH 
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key role in incentivizing vaccine innovation and cures related to viral infections. As 
is evidenced by the numerous patents awarded for biomedical-related technologies 
and methodologies used in the development of cures for past pandemics, suggesting 
that biomedical data can in fact be successfully incorporated into patented 
inventions. 
III. CAN PATENT LAW AND THE PROTECTION OF BIOMEDICAL DATA 
COEXIST? 
Arguably, the potential protections afforded to biomedical data by patent law 
leads to the conclusion that patent law can serve as an incentivization tool to develop 
methodologies and technologies to prevent future pandemics. Biomedical data 
“traditionally [has] had a key role in [the] scientific process.”38 Research and 
development of treatments utilizing such data “can yield patentable inventions and 
discoveries . . . such as newly identified genes [or] chemical entities that could 
eventually be marketed as drugs.”39 In fact, many scholars believe that patenting and 
licensing inventions incorporating biomedical data facilitates innovation by 
“provid[ing] [a] basis for seeking the investment for further research and 
development.”40 Additionally, biomedical data-driven patents help “accelerate 
exploration of particular paradigms” through the use of the best methods to create 
the invention claimed in the patent.41 Furthermore, these patents provide an effective 
means for scientists and researchers to use biomedical data to further the scientific 
process. This concept is addressed in some form in the U.S. and European patent law 
regimes as well as in international agreements and conventions—agreements and 
conventions to which the United States is a member. An overview of the U.S. and 
European patent law regimes is provided below, as well as an overview of 
international agreements. This overview seeks to highlight how different legal 
systems treat and protect inventions incorporating biomedical data under their 
respective patent law regimes. 
                                                          
38 Raul Rodriguez-Esteban & Markus Bundschus, Text mining patent for biomedical knowledge, 
21 DRUG DISCOVERY TODAY 997, 997 (2016), https://www.sciencedirect.com/science/article/pii/ 
S1359644616301520. 
39 Josephine Johnston & Angela A. Wasunna, Patents, Biomedical Research, and Treatments: 
Examining Concerns, Canvassing Solutions, 37 THE HASTINGS CTR. REP. 2, 8 (2007), https://www.jstor 
.org/stable/4625708. 
40 Id. at 11. 
41 See 35 U.S.C. § 112(a) (2018); see also Peter Lee, Patents, Paradigms Shifts, and Progress, 114 
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A. U.S. Patent Law Regime 
Under the U.S. patent law regime, rights are granted to the first inventor to file 
and allow the inventor “the right to exclude others from making, using, offering for 
sale or selling the invention.”42 However, to be granted a patent under the U.S. patent 
law regime, an invention must fall into one of the statutorily prescribed categories: 
process, machine, manufacture, or composition of matter.43 In addition, the invention 
must be novel, useful, and nonobvious.44 Further, the specification of the patent 
application must contain a written description which enables a person having 
ordinary skill in the art to make the invention, and the best mode for making such 
invention.45 
Patent protection has been granted for a wide array of scientific discoveries. 
More specifically, pharmaceutical patents have been granted for drug compounds, 
methods of use, and production process.46 Similarly, U.S. drug compound patents 
have been granted both for the active ingredient of pharmaceutical products and the 
method by which such products are used to treat specific illnesses.47 
B. European Patent Law Regime 
While many countries in Europe have their own patent offices and patent 
systems, a little more than half of the European countries’ patent systems are subject 
to the rules of the European Patent Convention (the “Convention”).48 The 
Convention establishes a Unitary Patent System among 25 European Union (EU) 
member states, which makes it possible for a patent applicant to obtain patent 
protection by submitting a single request to the European Patent Office.49 Prior to 
the implementation of the Unitary Patent System in 2013, the only approach to 
obtaining rights in Europe was to acquire rights through each country’s respective 
                                                          
42 35 U.S.C. § 154(a)(2) (2018). 
43 35 U.S.C. § 101 (2018). 
44 35 U.S.C. §§ 102, 103 (2018). 
45 35 U.S.C. § 112(a) (2018). 
46 Eileen M. Kane, Preparing for Pandemic Influenza: Achieving Clinical Equality in an Influenza 
Pandemic: Patent Realities, 39 SETON HALL L. REV. 1137, 1142 (2009). 
47 Id. 
48 Geertrui Van Overwalle, Policy Levers Tailoring Patent Law to Biotechnology: Comparing U.S. 
and European Approaches, 1 U.C. IRVINE L. REV. 433, 438 (2011). 
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patent office.50 This approach was disfavored by many because of the fragmented 
patent law protection it would produce.51 Prior to the Convention, patent applicants 
not only had to apply for protection in the each European Country, it had to enforce 
those protections on a country-by-country basis as well, incurring significant filing 
and litigation costs.52 However, many patent applicants now opt to file a patent 
through the European Patent Office where their patent rights are subject to the 
protections of the Convention.53 Such a filing prevents different interpretations by 
different countries of a patent applicant’s rights.54 The establishment of the unitary 
patent also led to the creation of the Unified Patent Court (UPC), which was granted 
exclusive jurisdiction to adjudicate unitary patent disputes.55 However, the UPC’s 
jurisdiction over European patents is not exclusive, allowing litigants to protect their 
patent rights in their respective national courts.56 This method is less favorable as the 
UPC allows for more consistency and predictability in patent litigation and 
protection.57 
Under the Convention, patents filed in member nations are granted in all fields 
of technology for inventions that are “new, involve an inventive step and [are] 
susceptible of [or used in] industrial application.”58 While the Convention prohibits 
patents for “methods for treatment of the human or animal body by surgery or 
therapy and diagnostic methods,” it allows patents for substances or compositions 
used in surgical, therapeutic, or diagnostic methods.59 In addition, the EU 
                                                          
50 Stuart J.H. Graham & Nicolas Van Zeebroeck, Comparing Patent Litigation Across Europe, A 
First Look, 17 STAN. TECH. L. REV. 655, 665 (2014). 
51 Michael J. Crowley, Restoring Order in European Patent Law: A Proposal for the 
Reintroduction of the Substantive Patent Provisions of the Unitary Patent Package into EU Law, 4 N.Y.U. 
J. INTELL. PROP. & ENT. L. 197, 200 (2015). 
52 Id. 
53 Overwalle, supra note 48, at 438. 
54 Kevin P. Mahne, A Unitary Patent and Unified Patent Court for the European Union: An 
Analysis of Europe’s Long Standing Attempt to Create a Supranational Patent System, 94 J. PAT. & 
TRADEMARK OFF. SOC’Y 162, 164 (2012). 
55 Crowley, supra note 51, at 202. 
56 Id. 
57 Joseph Kenneth Yarsky, Hastening Harmonization in European Patent Law Through 
Preliminary Reference Power, 40 B.C. INT’L & COMP. L. REV. 167, 168 (2017). 
58 The European Patent Convention, EUROPEAN PAT. OFF., https://www.epo.org/law-practice/ 
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Biotechnology Directive60 states that biological material isolated from its natural 
environment or produced by technical processes is patentable.61 Discovery of DNA 
sequences and the related methodology for discovery, on the other hand, is not 
eligible for patent protection.62 
C. International Agreements and Conventions 
The introduction of the Trade-Related Aspects of Intellectual Property Rights 
(TRIPS) Agreement in 1994 created new protections and mutual recognition of 
intellectual property rights among the 164 member countries.63 Such recognition is 
achieved through providing member countries intellectual property rights protection 
through respecting domestic laws, providing enforcement of such rights, and 
agreeing to handle disputes arising from the violation of patent rights through the 
World Trade Organization (WTO) dispute settlement system.64 While the TRIPS 
Agreement seeks to afford these protections, it does not mandate that member 
countries create identical or similar intellectual property regimes.65 Rather, countries 
maintain sovereignty with regard to intellectual property protection domestically. 
While the TRIPS Agreement expands intellectual property protections, it has 
created tensions between member countries’ intellectual property standards.66 The 
Agreement requires governments to grant patent rights in fields, such as generics and 
pharmaceuticals, that were deemed unpatentable in other regimes.67 In addition, the 
Agreement imposes more stringent compliance mechanisms than those enforced by 
individual member countries.68 Despite these tensions, the TRIPS Agreement has 
continued to protect both patent and other intellectual property rights effectively and 
has continued to foster innovation. 
                                                          
60 See Directive 98/44/EC of the European Parliament and of the Council, https://eur-
lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A31998L0044 (a 1998 directive harmonizing patent 
law among 27 member countries while providing for the legal protection of biotechnological inventions). 
61 Overwalle, supra note 48, at 445. 
62 Id. 
63 Marney L. Cheek, The Limits of Informal Regulatory Cooperation in International Affairs: A 
Review of the Global Intellectual Property Regime, 33 GEO. WASH. INT’L REV. 277, 287 (2001). 
64 Id. at 292. 
65 Id. 
66 Laurence R. Helfer, Regime Shifting: The Trips Agreement and New Dynamics of International 
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Similarly, the Paris Convention requires member states to extend the same 
protection granted to its own citizens to nationals of other member states.69 Under 
the Paris Convention, the grant of a patent in one member state does not preclude the 
inventor from obtaining a subsequent patent in another member state even if both 
patents claim the same or similar inventions.70 This ensures that “foreigners could 
not be excluded from obtaining patents in foreign countries” and “provide[s] 
assurances to inventors from one country that they could protect their invention in 
other countries as well.”71 Additionally, the Paris Convention creates a “uniform one-
year rule of priority,” allowing inventors a grace period between filing in various 
member countries.72 
The Patent Cooperation Treaty (PCT) serves as an alternative to the Paris 
Convention73 and allows inventors to simultaneously file patent applications in all 
member states.74 The PCT system implements an official international prior art 
search,75 which aids in the examination of the patentability of the claimed 
invention.76 Such search concludes with a written opinion detailing whether the 
application complies with the patentability criteria of the PCT.77 However, the non-
binding nature of the written opinion does not require members of the PCT to grant 
or deny a patent application in compliance with the opinion.78 The “final decision of 
granting a patent remains . . . at the sole discretion of the national or regional patent 
                                                          
69 Summary of the Paris Convention for the Protection of Industrial Property (1883), WORLD 
INTELLECTUAL PROP. ORG., https://www.wipo.int/treaties/en/ip/paris/summary_paris.html (last visited 
Apr. 2, 2021). 
70 Id. 
71 Brice C. Lynch, Note, International Patent Harmonization: Creating a Binding Prior Art Search 
Within the Patent Cooperation Treaty, 44 GEO. WASH. INT’L L. REV. 403, 412 (2012). 
72 Id. 
73 Juan Lapenne, Patent Cooperation Treaty (PCT), 92 J. PAT & TRADEMARK OFF. SOC’Y 192, 194 
(2010). 
74 Patent Cooperation Treaty, U.S. PATENT & TRADEMARK OFF., https://www.uspto.gov/patents-
getting-started/international-protection/patent-cooperation-treaty. 
75 What is Prior Art?, EUROPEAN PATENT OFF. (Sept. 15, 2015) (defining prior art as “any evidence 
that your invention is already known). 
76 Lapenne, supra note 73, at 195. 
77 Id. 
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offices.”79 Thus, the PCT provides applicants with predictability in regards to the 
likelihood of their inventions being patented.80 
The Paris Convention and PCT are two distinct agreements. However, they can 
be used together to provide patentees greater protection.81 Both the Paris Convention 
and Patent Cooperation seek to “streamline the acquisition of international patent 
rights.”82 While the main goal of the Paris Convention and the PCT is to harmonize 
filing between member states, these agreements do not prohibit the filing of 
inventions incorporating biomedical data or naturally occurring phenomena. Rather, 
the decision of patentability is placed with the individual member nations. Thus, 
nations that are part of either agreement and the Convention can still afford patent 
protection to inventions claiming isolation of DNA or genomic sequences, as well as 
chemicals and compounds used to treat viral illnesses and diseases. 
IV. PATENTING BIOMEDICAL DATA 
The U.S. and European Patent Regimes treat patenting biomedical data in two 
different ways. The U.S. patent system is more restrictive than the European patent 
system, declining to afford patent protection to inventions incorporating biological 
processes despite the potential utility of such inventions. The U.S. patent system 
requires inventions to fall into one of the statutorily prescribed categories. Those 
inventions that may potentially fall outside of the prescriptions are less likely to 
receive patent protection. However, in Europe, inventions do not have to explicitly 
fall into a statutorily prescribed category. Rather, as long as inventions are technical 
and have utility, they will be awarded patent protection.83 The distinction between 
the treatment of inventions incorporating biomedical data in the United States and 
European patent regimes is indeed stark. 
U.S. courts, for example, have hotly debated the patent eligibility of inventions 
incorporating biological processes.84 Notwithstanding this debate, the Supreme 
Court has held that “[granting] patents on medical relationships and isolated DNA 




82 John Gladstone Mills III, A Transnational Patent Convention for the Acquisition and 
Enforcement of International Patent Rights, 88 J. PAT. & TRADEMARK OFF. SOC’Y 958, 961 (2006). 
83 Guidelines for Examination, EUR. PATENT OFF., https://www.epo.org/law-practice/legal-texts/ 
html/guidelines/e/g_i_1.htm. 
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risk tying up the tolls of future innovation due to their broad scope.”85 This 
conclusion was the basis for rejecting patents incorporating biological processes in 
the Supreme Court’s Mayo and Myriad decisions. 
In Mayo Collaborative Services v. Prometheus Labs Inc., (“Mayo”), the 
Supreme Court tackled the question of whether the processes set forth in certain 
claims and which describe natural relations emanating from certain processes are 
patent eligible. The Court, in evaluating a process that assisted physicians in 
determining the appropriate dosage of thiopurine drugs to treat patients with 
autoimmune diseases, concluded that such a process did not adequately transform 
natural laws into patent eligible subject matter.86 In its conclusion, the Court held 
that “purely conventional or obvious presolution activity is normally not sufficient 
to transform an unpatentable law of nature into a patent eligible application of such 
law.”87 In the Court’s view, this is exactly what Mayo Collaborative Services sought 
to achieve in its patent application. The Court, in its decision, further noted that 
“phenomena of nature, though discovered, mental processes, and abstract intellectual 
concepts are not patentable, as they are the basic tools of scientific and technological 
work.”88 
Similarly, in Association for Molecular Pathology v. Myriad Genetics, Inc. 
(“Myriad”), the Supreme Court addressed the question of the validity of gene patents 
covering isolated DNA sequences. The Court determined that isolated naturally 
occurring DNA is not patent eligible.89 In its review, the Court analyzed whether the 
isolation of the cancer causing BRCA1 and BRCA2 genes were patent eligible under 
35 U.S.C. § 101. The Court’s determination was aided by the application of the 
“markedly different characteristics” test enumerated in Diamond v. Chakrabarty 
(“Chakrabarty”).90 Markedly different characteristics include “non-naturally 
                                                          
85 Johnathon Liddicoat, Kathleen Liddell & Mateo Aboy, The Effects of Myriad and Mayo on 
Molecular-Test Development in the United States and Europe: Interviews from the Frontline, 22 VAND. 
J. ENT. & TECH. L. 785, 789 (2020); see, e.g., Mayo Collaborative Servs. v. Prometheus Laboratories, 
Inc., 556 U.S. 66 (2012); Association for Molecular Pathology v. Myriad Genetics, 569 U.S. 576 (2013); 
but see Diamond v. Chakrabarty 447 U.S. 303 (1980). 
86 Mayo Collaborative Servs. v. Prometheus Laboratories, Inc., 556 U.S. 66, 72 (2012). 
87 Id. at 79. 
88 Id. at 70. 
89 Association for Molecular Pathology v. Myriad Genetics, 569 U.S. 576, 580 (2013). 
90 See Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980) (where a scientist sought patent 
protection related to his discovery of a method for developing a human-made genetically engineered 
bacterium that could break down multiple components of crude oil; the court holding that patents cannot 
protect laws of nature or physical phenomena; naturally occurring organisms to be patent eligible must 
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occurring manufactures or composition of matter, a product of human ingenuity 
“having distinctive name, character [and] use.”91 Applying this test, the Court 
reasoned that isolating DNA from its genetic material did not make it “markedly 
different” from its natural composition.92 The Court further justified its 
determination by noting that § 101 “contains an important implicit exception: [l]aws 
of nature, natural phenomena, and abstract ideas are not patentable”93 because 
granting patents in this area would “tie up the use of such tools and thereby inhibit 
future innovation premised upon them.”94 
The Court in these cases have outlined the scope of what constitutes patent 
eligible subject matter with regard to genomic DNA, medical techniques, and 
biomedical data.95 Academic studies have revealed the precedent setting value of 
these decisions on courts and agencies. For example, a study conducted by Professor 
Mateo Aboy, a visiting scholar in precision medicine, artificial intelligent, and law 
at Harvard University, revealed the United States Patent and Trademark Office 
routinely used the holding in Myriad to reject patents involving peptides, proteins, 
antibodies, cells, and pharmaceutical compositions.96 Lower courts have used the 
holdings and reasoning in both Mayo and Myriad to invalidate patents claiming the 
application of conventional molecular DNA isolation techniques and technologies.97 
Notwithstanding this trend, the Federal Circuit in 2018 determined that companion 
diagnostics98 or non-natural biologic processes are patent eligible if the drug claimed 
is unconventional or if the steps claimed “amount to more than merely diagnosing a 
patient and instructing a doctor to generically treat it.”99 
                                                          
91 Id. at 310. 
92 Myriad Genetics, 569 U.S. at 591. 
93 Id. at 589 (quoting Mayo, 566 U.S. at 70). 
94 Id. 
95 Liddicoat, Liddell & Aboy, supra note 85, at 787. 
96 Id. at 792 (citing Mateo Aboy et al., Was the Myriad Decision a “Surgical Strike” on Isolated 
DNA Patents, or Does it Have Wider Impacts?, 36 NATURE BIOTECHNOLOGY 1146 (2018)). 
97 Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371, 1371 (Fed. Cir. 2015). 
98 Companion Diagnostics, U.S. FOOD & DRUG ADMIN. (Dec. 7, 2018), https://www.fda.gov/ 
medical-devices/vitro-diagnostics/companion-diagnostics (defining companion diagnostics as a medical 
device providing information essential for the safe administration of a corresponding drug or biological 
product). 
99 Liddicoat, Liddell & Aboy, supra note 85, at 795–95; see also Vanda Pharmaceuticals, Inc v. 
West-Ward Pharmaceuticals International Ltd., 887 F.3d 1117, 1135–36 (Fed. Cir. 2018); Rapid Litig. 
Mgmt. v. CellzDirect, Inc., 827 F.3d 1042, 1047 (Fed. Cir. 2016) (holding that “the natural ability of 
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Given its attempt to definitively determine the patentability of biomedical data, 
the Court in Mayo and Myriad left a gap by leaving open the question as to the 
patentability of genetic information. More specifically, the courts “failed to answer 
exactly how much researchers can modify a gene before it becomes patent 
eligible.”100 Additionally, the Court left open the question as to “whether the legal 
system should [consider the patent eligibility of] DNA based on its chemical 
structure or based on the information it encodes.”101 
However, European law has taken a different approach to ensure that inventors 
understand the limits of patenting biomedical data-related inventions. In efforts to 
increase innovation implementing biomedical data, the EU implemented the Biotech 
Directive, which sought to affirmatively define the bounds of patenting biotech 
inventions.102 Under this directive, in order for subject matter to be patent eligible it 
must be technical in nature or have utility.103 More specifically, the directive states 
that 
[S]uch an element isolated from the human body or 
otherwise produced is not excluded from patentability 
since it is . . . the result of technical processes used to 
identify, purify and classify it and to reproduce it outside 
the human body, techniques which human beings alone 
are capable of putting into practice and which nature is 
incapable of accomplishing by itself.104 
Thus, DNA, RNA, and other genetic materials are eligible for patent protection under 
the European Patent Law Regime because their isolation “make[s] something 
available to the public that previously was not.”105 
As a result, the European patent regime affords broader protection for 
inventions incorporating biomedical data. In fact, “European equivalents of the 
patents considered in Myriad [and] Mayo were treated differently than in the U.S.”106 
The standard by which the European patent system evaluates patent eligible subject 
                                                          
100 Carrie Arnold, Gene Patents Remain Controversial in Biomedical Research, THE LANCET 
(Aug. 10, 2013), https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)61698-0/fulltext. 
101 Id. 
102 Jessica C. Lai, Myriad Genetics and the BRCA Patents in Europe: The Implications of the U.S. 
Supreme Court Decision, 5 U.C. IRVINE L. REV. 1041, 1044 (2015). 
103 Id. at 1046. 
104 EU Biotech Directive, EUR-Lex (July 6, 1998), https://eur-lex.europa.eu/eli/dir/1998/44/oj. 
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matter is more conducive to ensuring that inventions seeking to help prevent viral 
outbreaks are patented. This is evidenced by various patents awarded to inventions 
encompassing biomedical data throughout Europe. For example, the European 
Patent Office awarded to the University of Utah a patent claiming the creation of the 
method for diagnosing a predisposition for breast and ovarian cancer.107 
Additionally, a European patent was awarded to the University for the identification 
of the naturally occurring genetic mutations linked to increasing a patient’s 
susceptibility of ovarian and breast cancer.108 Further, in 2017, the German Federal 
Court of Justice (Bundesgerichtshof—Germany’s highest patent court) concluded 
that the “disclosure of how to create a [DNA] sequence through a technical process 
such as isolation” is patentable.109 
V. MODIFICATION OF THE UNITED STATES PATENT REGIME  
Prior to the Mayo and Myriad decisions, isolated DNA was patentable under 
the United States patent regime. However, U.S. Supreme Court jurisprudence barred 
patents claiming isolated DNA and other naturally occurring processes. Despite the 
rulings in Mayo and Myriad, the Supreme Court did not clearly define a “natural 
product.” This left patent seekers without sufficient guidance as to what is considered 
patent eligible and limited the scope of medical patents, despite the rise in both 
technology and biomedical data. Thus, it is essential to modify the grant of patents 
in the field of biomedical data and encourage innovation and provide inventive 
protection to researches and inventors who seek to introduce new methods of 
identifying and curing viral infections. This can be done through the Supreme 
Court’s revisit and implementation of the standard set forth in Diamond v. 
Chakrabarty. Additionally, overturning Mayo and Myriad would expand the patent 
eligible subject matter to include biomedical data. Lastly, taking on the policies of 
international trade agreements and conventions may result in more expanded 
treatment of patent protection and encourage innovation. 
                                                          
107 European Patent No. T 0080/05 (Method of diagnosis/University of Utah) (decided Nov. 19, 
2008), https://www.epo.org/law-practice/case-law-appeals/recent/t050080eu1.html. 
108 European Patent No. T 1213/05 (Breas and ovarian cancer/University of Utah) (decided 
Sept. 27, 2007), https://www.epo.org/law-practice/case-law-appeals/recent/t051213eu1.html. 
109 Case law from the Contacting States to the EPC, EUROPEAN PATENT OFF. (Dec. 15, 2017), 
https://www.epo.org/law-practice/legal-texts/official-journal/2017/etc/se6/p12.html; see also Mateo 
Aboy et al., How does emerging patent case law in the US and Europe affect precision medicine, 37 
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A. The Diamond v. Chakrabarty Standard 
The United States Supreme Court was tasked with interpreting 35 U.S.C. § 101 
in Diamond v. Chakrabarty in 1980. The Court held that Congress intended statutory 
subject matter to include “anything under the sun that is made by man.”110 Thus, 
respondent’s micro-organism qualified as patentable subject matter because it was 
“a product of human ingenuity having a distinctive name, character and use.”111 
Under this standard, the United States provided the broadest protection for 
biomedical inventions, ranging from gene isolation to other genetic treatments and 
processes.112 Implementing the Chakrabarty standard would render inventions 
incorporating biomedical data patent eligible because they would be the product of 
“human ingenuity” through manipulation, isolation, and testing. More specifically, 
implementing this standard would allow for scientific methods and discoveries used 
to develop new vaccines and cures for viral infections to be awarded patent 
protection. 
B. The Supreme Court Should Reverse Mayo and Myriad to Expand 
Patent Eligible Subject Matter 
The decisions in both Mayo and Myriad significantly limit the potential to 
incorporate genetic and biomedical discoveries into patent eligible inventions. As the 
use of technology in science expands, the holdings in these two cases could 
potentially adversely impact patenting methodologies and medicines used in curing 
and preventing viral infections and addressing pandemics now and in the future. 
These decisions could have a chilling effect on innovation to the extent that inventors 
may no longer be incentivized to innovate, knowing their inventions will not be 
protected. Such an adverse impact on innovation may require the Supreme Court to 
overturn Mayo and Myriad and revert back to the Chakrabarty standard. 
C. Implementing the Policies of International Trade Agreements  
Even though the United States is a party to the Paris Convention, the TRIPS 
Agreement, and the Patent Cooperation Treaty it still fails to treat inventions 
incorporating biomedical data the way other countries that are parties to those 
agreements do. For example, under the Japanese Patent Regime, inventions with 
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industrial applicability are patent eligible.113 However, activities that are normally 
attributable to doctors such as surgery, therapy, or diagnoses fall outside of patent 
eligible subject matter.114 Despite this exception, inventions that can be 
manufactured and sold, including compounds, compositions, and methods of making 
such inventions, are patent eligible.115 Thus, inventions incorporating biomedical 
data to assist in isolating viruses or creating new vaccines to cure viruses would be 
eligible for patent protection in Japan. Similarly in Europe, inventions incorporating 
biomedical data are patent eligible if they are produced via a technical process.116 
Even if substances and compositions are part of the prior art, if they are used for a 
surgical, therapeutic, or diagnostic purpose for the first time, patent protection can 
be granted.117 If the United States Patent Regime adopts policies similar to Japan and 
Europe, inventions using biomedical data to find cures and prevent future pandemics 
would be patent eligible subject matter. There would be no need for the United States 
Patent Office or the courts to scrutinize inventions created to help prevent global 
public health crises. 
VI. CONCLUSION 
Biomedical data and patent law can work in parallel and eventually intersect to 
prevent future pandemics. The theories proposed in this Note do not cover all of the 
possible methods that potentially exist to create greater interaction between the fields 
of biomedical data and patent law. However, these theories can be used as starting 
points in analyzing how the two fields can work in conjunction with one another to 
prevent future pandemics. While current Supreme Court precedent disqualifies 
genetic DNA isolation processes and medical techniques as patent eligible subject 
matter, the shift in biomedical data for scientific advancement may result in an 
altered interpretation of 35 U.S.C. § 101. In contrast to the United States, patent 
systems in Europe and Japan, for example, afford broader protection to inventions 
encompassing biomedical data. Key international agreements to which the United 
States is a party, follow this trend. Therefore, American inventors and researchers 
may find protection through the TRIPS Agreement, the EU Biotech Directive, the 
Paris Convention, and the Patent Cooperation Treaty, until patenting inventions 
involving biomedical data becomes normalized in the U.S. patent law regime. 
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